Gsk Share Discussion Threads

[gbh2] 18/10/2024 15:13

Been a while but back in to see where it goes from here.

[tradermichael] 18/10/2024 14:55

IN @ 1468.825 ..... ;0)

[dplewis1] 18/10/2024 14:29

Well you did warn everyone I suppose :)

[rikky72] 18/10/2024 14:10

I actually used the dive in recent price to bed and ISA most of mine so every cloud..

[dope007] 18/10/2024 14:04

Added final trance using dividends today

[rikky72] 18/10/2024 14:02

Not GSK-specific, whole market a sea of red today.

[pander45] 18/10/2024 13:50

This is being relentlessly dumped.

[pander45] 18/10/2024 13:45

Dive dive dive! 1300 incoming.

[dope007] 18/10/2024 12:54

Most UK shares are not responding to anything

[tradermichael] 18/10/2024 12:16

And regular good product/business news, yet share price not responding.

[justiceforthemany] 18/10/2024 11:20

Zantac issue almost cleared up and for a lot less than feared yet share price not responding.

[tradermichael] 18/10/2024 06:13

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s share price up 63%.
GSK paid $170 million to close a deal that included global rights to WVE-006 in 2022. Wave will wrap up the current study of WVE-006 and then hand over to GSK, which is on the hook for up to $525 million in milestones, for further development.

[keyno] 17/10/2024 14:18

I've bought back in here after quite a while. Looking for diversity and yield - as well as great things. (Time is a great healer .....) Apologies to all longs in advance - my timing is usually poor.

[tradermichael] 17/10/2024 13:46

Any morning gains seem to be routinely reversed with Wall Street opening

[tradermichael] 16/10/2024 19:49

VERY IMPORTANT:

Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents

Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials - 26 March 2025 assigned as action date for FDA decision.

Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years.

[rikky72] 15/10/2024 15:06

We need them to disagree a lot..

[dplewis1] 15/10/2024 14:37

The US disagree

[patientcapital] 14/10/2024 15:37

Currency movements have also been a headwind.

[tradermichael] 14/10/2024 14:58

Yes, there's been a lot of good news flow all year and the neutral response in the share price seemed to have been attributed to the litigation issue. Now that's gone, there's still some ill sentiment. It will take time, rather than positive news for that to dissolve.

[rikky72] 14/10/2024 14:09

I must say I feel a lot less bullish after witnessing the very poor share price reaction to the Zantac news. Seems like we need a lot of good news flow before this can get motoring again.

[tradermichael] 14/10/2024 13:07

Many brokers citing 1820 to 1850p (Citigroup 1900p)

[dplewis1] 14/10/2024 10:50

Guggenheim cuts target price to 1785p from 1898p

[tradermichael] 14/10/2024 09:34

Your >25 years dividends (especially if used to buy more GSK as you go) would have been worth a great deal more than the 3% that you are up. Do the calculation and consider continuing with GSK for your income portfolio.